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Abstract
We report a genome-wide association follow up study on prostate cancer. We identify four
variants associated with the disease in European populations: rs10934853-A (OR = 1.12, P =
2.9×10−10) on 3q21.3, two moderately correlated (r2 = 0.07) variants on 8q24.21; rs16902094-G
(OR = 1.21, P = 6.2×10−15) and rs445114-T (OR = 1.14, P = 4.7×10−10) and rs8102476-C (OR =
1.12, P = 1.6×10−11) on 19q13.2. We also refine a previous association signal on 11q13 with the
SNP rs11228565-A (OR =1.23, P = 6.7 × 10−12). In a multi-variant analysis, using 22 prostate
cancer risk variants typed in the Icelandic population, we estimate that carriers belonging to the
top 1.3% of the risk distribution have a risk of developing the disease that is more than 2.5 times
greater than the population average risk estimates.
We and others have previously presented results from genome-wide association studies
(GWAS) on prostate cancer reporting several common variants conferring risk of the
disease1-7. By scrutinizing both our Icelandic GWAS data and publicly available data, as
well as through fine-mapping work of two previously published loci on 8q24.21 and 11q13,
we identified four new variants conferring risk of prostate cancer and a variant refining the
previously published association signal on 11q13.
In order to search for prostate cancer risk variants, we performed an analysis of the
combined data from the Icelandic GWAS, generated using the Illumina 317K chip, and from
the replication genotyping project, released (spring 2008) by the National Cancer Institute
Cancer GeneticMarkers of Susceptibility (CGEMS), using 25K SNPs genotyped on five
study populations, including PLCO, CPS-II, HPFS, FPCC and ATBC5,7. In the combined
study, when excluding regions containing previously reported prostate cancer risk variants,
only two SNPs have P < 1×10−5. These two new variants are: allele A of rs10934853
(rs10934853-A) located on 3q21.3 (a fully correlated marker used from the CGEMS data is
rs4857841 with D’ and r2 = 1 according to CEU HapMap, Supplementary Table 1); allelic
odds ratio (OR) of 1.14 and P = 1.6×10−7 and allele C of rs8102476 (rs8102476-C) located
on 19q13.2; OR of 1.11 and P = 2.6×10−6. In the combined study of the Icelandic and
CGEMS data, when analyzing variants located within 1 Mb regions of previously published
prostate cancer risk loci, we found only the SNP rs445114, located on 8q24.21, to be
associated with prostate cancer (OR = 1.14, P = 3.1×10−8) and not to be correlated with
other signals at any of the previously reported prostate cancer loci.
As a part of ongoing fine-mapping project on the three previously published variants on
8q24.21 we re-sequenced a 527 kb candidate region on 8q24 using pools of either Icelandic
case or control samples (see Online Methods). We prioritized the analysis of 7 SNPs
producing suggestive association results for prostate cancer in the analysis of the pooled
samples (Supplementary Table 1). These 7 SNPs were genotyped, using Centaurus single
track assay, in our Icelandic set of up to 1,980 patients and 7,000 controls. Six of the SNPs
were found to be correlated with one of the previously reported variants on 8q24, while
rs16902094 was not found to be correlated with any of the previously reported prostate
cancer variants on 8q24.21 (Supplementary Tables 1 and 2). Furthermore, rs16902094 was
found to be associated with prostate cancer in Iceland, having an OR of 1.28 (P = 3.5×10−6;
Table 1). rs16902094 is not present on the Illumina Hap 317K SNP chip and no data are
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available for it in the HapMap project according to HapMap’s official website. However, by
genotyping SNPs located within the same LD-region as rs16902094 and that are present on
the Illumina Hap 550 chip, we identified a highly correlated SNP rs16902104 (D’ = 0.98, r2
= 0.96 according to data from 2,633 Icelanders; Supplementary Table 1) which CGEMS has
released data for. By combining the Icelandic data for rs16902094 and the CGEMS data for
rs16902104 we obtained an OR of 1.21 (P = 1.1×10−9).
The two new SNPs on 8q24.21, rs16902094 and rs445114, are located in the same LD-
region but the correlation between them is very low (D’ = 1 and r2 = 0.07 according to data
from 5,450 Icelanders; Supplementary Table 1) and the results for both remain significant
after adjustment for the other (Supplementary Table 3a). This suggests that a unique variant
capturing the effect of both rs16902094 and rs445114 remains to be discovered or,
alternatively, that the LD-region contains more than one variant that predisposes to prostate
cancer. Of the previously published cancer variants on 8q24, only the breast cancer variant
(rs13281615)8 is located within the same LD-region as the two new 8q24 SNPs and
rs445114 is somewhat correlated with it (D’ = 0.76, r2 = 0.44; Supplementary Table 2),
while rs16902094 is much less correlated with it (D’ = 0.61, r2 = 0.06; Supplementary Table
2). However, both rs16902094 and rs445114 show very little correlation with any of the
previously published prostate1,2,7,9-, colon10-12-, or bladder cancer13 risk variants on 8q24
(D’ ≤ 0.6 and r2 ≤ 0.13; Supplementary Table 2 and Supplementary Fig. 1). The results in
Iceland for rs16902094, rs445114 and the three previously published prostate cancer risk
variants on 8q24, remain significant after being adjusted for each other (Supplementary
Table 3b). Hence, rs16902094 and rs445114 should be included in the list of variants at
8q24 associated with prostate cancer risk. The five 8q24 variants conferring risk of prostate
cancer are distributed between four LD-regions, spanning approximately 480 kb. One of the
five prostate cancer risk variants, rs6983267, has been shown to also affect the risk of
colorectal cancer. Other cancer risk variants on 8q24.21, conferring risk of breast or bladder
cancer, have not been shown to predispose to prostate cancer13,14.
We proceeded to genotype all the four newly discovered SNPs (rs10934853 on 3q21.3,
rs8102476 on 19q13.2 and rs16902094 and rs16902104 both on 8q24.21) in at least two out
of five prostate cancer study groups (deCODE follow up groups) of European descent.
These groups come from The Netherlands, Spain, Finland and the United States (US) (see
Supplementary Note). When results for SNPs successfully genotyped in these groups were
combined with the Icelandic and CGEMS data discussed above, they were significant for all
loci, surpassing the threshold of genome-wide significance set by many at P > 10−7. By
examining the literature we found that Duggan et al.15 had published data (OR = 1.21, P =
0.045) for rs10934853, on 3q21.3, from a study on aggressive prostate cancer in the CAPS
study population from Sweden. Thereby, adding further significance to the combined
analysis of the 3q21.3 locus (see Table 1 for combined OR and P-values).
When inspected, a test of heterogeneity in the OR for all variants and all study groups
showed a nominally significant heterogeneity (Phet = 0.039) for the 3q21.3 locus, no
significant difference was observed for the other three loci (Phet > 0.1). For rs10934853 on
3q21.3 the estimated OR tended to be greater for the combined US study groups (OR =1.21
and the 95% CI: 1.13, 1.28) than for the combined European study groups (OR = 1.08 and
the 95% CI: 1.04, 1.13). This observation, while interesting, needs to be further confirmed.
A prostate cancer risk variant, with an allelic frequency of about 0.5 and located on 11q13,
was reported previously by two groups independently; Thomas et al.5 reported rs10896449,
and Eeles et al.4 reported rs7931342 (the two SNPs are highly correlated with D’ = 1 and r2
= 0.97 according to Utah CEPH (CEU) HapMap data). In the Icelandic GWAS data set, the
strongest association with prostate cancer on 11q13 was observed for allele G of rs10896450
Gudmundsson et al. Page 3
Nat Genet. Author manuscript; available in PMC 2013 February 03.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(OR = 1.13, P = 2.5 ×10−4; Table 2), a SNP highly correlated with the two previously
reported SNPs (D’ = 1; r2 > 0.97 according to CEU HapMap data). In order to investigate
further the 11q13 locus, we selected six SNPs not present on the Illumina Hap300 chip but
moderately correlated with each of the three anchor SNPs: rs10896449, rs7931342, and
rs10896450 (D’ ≥ 0.70 and r2 > 0.24 according to CEU HapMap data; Supplementary Table
1). Furthermore, these SNPs are not strongly correlated with any SNP on the Illumina
Hap300 chip (r2 < 0.8). By doing this, we attempted to find variants with greater risk and
lower allelic frequency. The additional six SNPs were genotyped in 1,809 and 783 Icelandic
cases and controls, respectively. The control individuals were randomly selected from the
Icelandic population and were not known to have prostate cancer according to the
nationwide Icelandic Cancer Registry (see URL below). Allele A of the refinement SNP
rs11228565 was found to confer greater risk of the disease than the anchor SNP
(rs10896450), with an OR of 1.24 (P = 0.0057) and a control frequency of 0.177 in the
Icelandic study group (Table 1 and Supplementary Table 4). We then tested the two SNPs,
rs10896450 and rs11228565, in the five deCODE follow up groups. For the Finnish study
group, instead of genotyping rs10896450, we used data available for the highly correlated
SNP rs7931342 (D’ = 1; r2 > 0.97 according to CEU HapMap data), previously reported by
Kote-Jarai et al16. Combination of the results from Iceland and the deCODE follow up
groups gave an estimated OR of 1.15 (P = 2.6 × 10−8) for rs10896450-G whereas for
rs1128565-A the OR was estimated to be 1.23 (P = 6.7×10−12) (Table 1 and Supplementary
Table 5). The estimated frequency of the risk allele of rs11285565 in the combined data set
of the groups used in this study is 0.20 compared to 0.50 for the G allele of rs10896450
(Supplementary Table 5). Hence, the frequency of the risk allele for the new SNP is lower
than for the previously reported one. Also, the point estimate of the OR is greater (OR =
1.23 for rs11285565 vs. 1.15 for rs10896450) although the difference is not significant, (P =
0.08 using results for all study groups; Supplementary Table 5). The results for rs11228565
were strongest for the study groups from Nashville and Finland but weakest for the Spanish
group. However, a test of heterogeneity in the OR of all study groups showed no significant
difference for the 11q13 locus (P = 0.26). When adjusting the results for the refinement SNP
(rs11228565-A) using data the anchor SNPs, (rs10896450-G or rs7931342-G), it remained
significant (OR = 1.19, P = 5.0 × 10−7) while the anchor SNPs were not significant after
being adjusted for the refinement SNP (OR = 1.03, P = 0.15; Supplementary Table 5).
For the six study groups of European descent (excluding the five CGEMS groups and the
study by Duggan et al15.), where we had information about age at diagnosis, no age effect
was seen for any of the five loci discussed above (P ≥ 0.3). By computing the genotype
specific ORs or inspecting the genotypic ORs from the public CGEMS data set for the
variants in Table 1, we found that the multiplicative model provides an adequate fit for all
five loci in the study groups analyzed (for the full- vs. the multiplicative model all P > 0.1;
Supplementary Table 6 and Online Methods). Comparing the patients with a more
aggressive phenotype (Gleason ≥7 and/or T3 or higher and/or node positive and/or
metastatic disease) to the group with less aggressive tumors (Gleason <7 and T2 or lower)
showed no difference; an OR between 0.94 and 1.03 (P > 0.1) was observed for the five loci.
The public CGEMS data also showed no difference between patients with more or less
aggressive disease (P > 0.40) for the SNPs where data are available (3q21, 8q24, and
19q13.2). The study published by Duggan et al15. was on aggressive prostate cancer only
and a comparison with less aggressive disease was therefore not possible.
The four novel loci reported here, add to the rapidly increasing number of prostate cancer
susceptibility variants, identified through GWASs. In Table 2, we provide results from the
Icelandic GWAS for risk variants reported by us and/or others (until February 2009) to
confer risk of prostate cancer. For some of the SNP associations reported in other
populations, the Icelandic results provide replication (in particular 7p15 and 10q11), while
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we failed to replicate association for other SNPs in this population (in particular 9q33 and
22q13). In order to summarize the overall effect of the variants in Tables 1 and 2 we
combined the effect of all variants affecting risk of prostate cancer in the Icelandic
population., We performed a multi-variant analysis, using the multiplicative model for 22
risk variants. Testing the assumptions, no significant deviation from the multiplicative
model was observed for any given variant as well as no interaction between variants (see
Online Methods). Based on this analysis, the estimated risk is more than 2.5-fold greater for
the top 1.3% of the risk distribution (including 0.3% of the population with a risk greater
than 3), using the population average risk as a reference (Table 3). For these individuals this
corresponds to a lifetime risk of over 30% of being diagnosed with prostate cancer,
compared with a risk of 12%, on average in Iceland, of getting the disease before age 75,
according to NORDCAN (see URL below) assuming no interaction between the effect of
the variants and age at diagnosis. The combined risk estimates presented here are similar to
those previously reported by Kote-Jarai et al. for 15 risk variants16. We note that the
estimates provided here are based solely on our Icelandic study population, and that more
accurate estimates could be obtained from large prospective studies. Also, given the fast
pace of discoveries in the current era of GWASs, more variants associated with prostate
cancer risk are likely to be discovered, which suggests the need for constant updating of
such multivariant risk models.
Online Methods
Genotyping Methods
Illumina genotyping—1,968 and 35,382 Icelandic case- and control-samples
respectively, were successfully assayed with the Infinium HumanHap300 SNP chip
(Illumina, SanDiego, CA, USA), containing 317,503 haplotype tagging SNPs derived from
phase I of the International HapMap project. Of the SNPs assayed on the chip, 2,906 SNPs
had a yield lower than 95%, 271 SNPs had a minor allele frequency, in the combined set of
cases and controls, below 0.01 or were monomorphic. An additional 4,632 SNPs showed a
significant distortion from Hardy-Weinberg equilibrium in the controls (P < 1.0×10−3). In
total, 6,983 unique SNPs were removed from the study. Thus, the analysis reported in the
main text utilizes 310,520 SNPs. Any samples with a call rate below 98% were excluded
from the analysis.
Replication genotyping—Single SNP genotyping of the SNPs reported in the main text
for the four case-control groups from Iceland, The Netherlands, Spain and Chicago was
carried out by deCODE Genetics in Reykjavik, Iceland, applying the Centaurus20 (Nanogen)
platform. The quality of each Centaurus SNP assay was evaluated by genotyping each assay
in the CEU and/or YRI HapMap samples and comparing the results with the HapMap
publicly released data. Assays with >1.5% mismatch rate were not used and a linkage
disequilibrium (LD) test was used for markers known to be in LD. We re-genotyped more
than 10% of the samples and observed a mismatch rate lower than 0.5%. Genotyping of
samples from Finland and Nashville was done using the same Centaurus assays as used in
Iceland at the University of Tampere and Vanderbilt University, respectively, using standard
protocols.
For each of the SNPs discussed in the main text, the yield was higher than 95% for those
samples which genotyping was attempted for in every study group. The SNPs rs16902094
on 8q24 and rs11228565 on 11q13 are not present on the Human Hap300 chip. Therefore,
using a single SNP assay for genotyping, an attempt was made to genotype 6,900 and 800
individuals, respectively, of the 35,382 Icelandic controls as well as 1,860 Icelandic cases
and all available individuals from the replication study groups.
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Discovery of new SNP on 8q24 by Solexa re-sequencing—In order to search for
new SNPs on 8q24, a 527 kb region (128113108 – 128640337 bp, Build 36) was sequenced
using the Solexa re-sequencing platform (Illumina Inc.). From our set of ~2,000 cases, 800
were selected randomly and split into two DNA-pools, each with 400 samples. Similarly,
800 control individuals, not known to have prostate cancer, were selected randomly and split
into two DNA-pools. Dilutions were prepared in duplicates for the 4 pools and used for
longe-range PCR reactions (each amplimer consisted of about 10 kb). PCR fragments were
run on 0.8% agarose gels and the DNA visualized with BlueView (Sigma Inc.) under normal
light and their sizes estimated with HindIII digested lambda size marker (Fermentas Inc).
Bands of correct sizes were excised out of the agarose gels and purified with Qiagen gel
extraction kit (Qiagen Inc.). The PCR products were quantified by picogreen assay
(Invitrogen Inc.) as described by the manufacturer. The preparation of the Solexa DNA
libraries, the cluster generation and DNA sequencing was done was done as described by
Bentley et al21. The SNP Analysis pipeline is composed of four components: Alignment,
SNP calling, Filtering and Association analysis. Promising SNPs were selected for further
study/confirmation using Centaurus single track SNP assays.
Statistical analysis
Association analysis—For SNPs that were in strong LD, whenever the genotype of one
SNP was missing for an individual, the genotype of the correlated SNP was used to provide
partial information through a likelihood approach as previously described9. This ensured
that results presented in Supplementary Table 5 were based on the same number of
individuals, allowing meaningful comparisons of results for correlated SNPs. A likelihood
procedure described in a previous publication22 and implemented in the NEMO software
was used for the association analyses.
We tested the association of an allele to prostate cancer using a standard likelihood ratio
statistic that, if the subjects were unrelated, would have asymptotically a χ2 distribution
with one degree of freedom under the null hypothesis. Allelic frequencies rather than carrier
frequencies are presented for the markers in the main text. Allele-specific ORs and
associated P values were calculated assuming a multiplicative model for the two
chromosomes of an individual23. Results from multiple case-control groups were combined
using a Mantel-Haenszel model24 in which the groups were allowed to have different
population frequencies for alleles, haplotypes and genotypes but were assumed to have
common relative risks (see Gudmundsson et al.3 for a more detailed description of the
association analysis).
The control groups from Iceland, The Netherlands, Spain, and Finland include both male
and female controls. No significant difference between male and female controls was
detected for SNPs presented in Table 1 for each of these four groups. Controls from other
study groups include only males.
In order to assess the association for the SNP rs4962416 on 10q26, which is in the CEU
section of the Hapmap database but absent from the Illumina Hap300 chip, we use a method
based on haplotypes of two markers (rs7077275 and rs893856) present on the chip. We used
a method we have previously employed25, that is an extension of the two-marker haplotype
tagging method26 and is similar in spirit to two other proposed methods27,28. We computed
associations with a linear combination of the different haplotypes chosen to act as surrogates
to HapMap markers in the regions. These calculations were based on 1,724 prostate cancer
cases and 35,322 controls genotyped on chip.
Multivariant analysis—In a multi-variant analysis, we combined the effect of 22 variants
affecting risk of prostate cancer using estimates based on data from only the Icelandic study
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group. A multiplicative model was assumed at each variant and between all variants. For the
21 autosomal variants we tested for deviation from the multiplicative model comparing it to
the full model of genotypic odds ratio (OR). No significant (given the number of tests
performed) deviation from the multiplicative model was detected (all P-values > 0.0024,
corresponding to 0.05 divided by 21). For the variant located on the X chromosome
(rs5945572), there exist only two male genotypes (carrier and no-carrier). Also, we tested
the pair-wise interactions between the 22 risk variants using logistic regressions including
terms corresponding to the 231 possible pairs. No significant (given the number of tests
performed) deviation from the multiplicative model was detected with a level of significance
below 0.00022 (corresponding to P = 0.05 divided by 231). Similarly, the absence of
interaction between variants has previously been reported by others5,16,29. Odds ratios were
calculated for all possible genotype combinations based on these 22 variants and expressed
relative to the average general population risk. The combined OR estimates were then
divided into OR-ranges and presented along with the percentage of the population within
each OR-range (See Table 3 in the main text). The general population risk was determined
using a frequency-weighted average risk for all possible genotypes.
The Icelandic samples were part of the initial discovery study populations for 10 of these 22
variants, therefore the estimates for these may be inflated due to winners curse. From Table
1 we are using the estimates for the following variants: rs10934853 on 3q21.3, rs11228565
on 11q13 and rs8102476 on 19q13.2. For the five variants (rs1447295, rs6983267,
rs16901979, rs16902094 and rs445114) on 8q24.21 we are using the adjusted estimates as
reported in Supplementary Table 3b. From Table 2, we use the estimates for all variants
except rs1571801 on 9q33 since its effect was in the opposite direction compared to the
original publication, and rs10896450 on 11q13 for which data for the refinement SNP
(rs11228565) in Table 1 was used. Furthermore, for the two variants on 17q12, reported in
Table 2, we are using the estimates adjusted for each other since the two markers are located
~25 kb to each other although not correlated (D’ = 0.03, r2 = 0.0004 according to CEU
HapMap data); rs4430796 has an adjusted OR of 1.17 and rs11649743 has an adjusted OR
of 1.06.
We apply the combined genetic relative risk to the lifetime risk by multiplying them
together. Since the association with the disease for these variants has not been shown to
depend on age at diagnosis3,16, we assume that the individual estimates for each variant will
have a similar effect at any given age. The lifetime risk of getting prostate cancer is
estimated to be 12%, on average in Iceland, before the age of 75, according to NORDCAN
(see URL).
Analysis of the CGEMS data—For the five individual study populations from the
CGEMS study5,7 (ACS = American Cancer Society Prevention Study II (US); ATBC =
Alpha-Tocopherol, Beta-Carotene Prevention Study (Finland); FPCC: CeRePP French
Prostate Case-Control Study (France); HPFS = Health Professionals Follow-up Study (US);
PLCO = Prostate, Lung, Colon, Ovarian Trial (US)), when assessing the allelic effect we
used the pre-computed data (released in spring, 2008) corresponding to “All case versus
control (dichotomous), genotype trend effect model, adjusted”. When assessing the
genotypic effect at each loci for the CGEMS study we used the pre-computed “All case
versus control (dichotomous), genotype-specific effect model, adjusted, ALL (ACS, HPFS,
FPCC, ATBC, PLCO)”.
Correction for relatedness—Some individuals in the Icelandic case-control groups were
related to each other, causing the aforementioned χ2 test statistic to have a mean >1. We
estimated the inflation factor by using a previously described procedure30 in which we
simulated genotypes through the genealogy of the 37,350 Icelanders analyzed in the present
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study (number of simulations = 100,000). The inflation factor was estimated to be 1.10.
Results from the Icelandic samples presented in the main text are based on adjusting the χ2
statistics by dividing each of them by 1.10.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank the individuals who participated in the study and whose contribution made this work possible. This
project was funded in part by contract number 202059 (PROMARK) from the 7th Framework Program of the
European Union to deCODE genetics (T.R., and L.A.K.), in part by FP7-MC-IAPP Grant agreement no.: 218071
(CancerGene) to deCODE genetics, in part by a V Foundation award and US Department of Veterans Affairs grants
to J.R.S, and in part by Academy of Finland, Sigrid Juselius Foundation, Finnish Cancer Organisations and the
Competitive Research Funding of the Pirkanmaa Hospital District, Tampere University Hospital to J.S.
References
1. Gudmundsson J, et al. Genome-wide association study identifies a second prostate cancer
susceptibility variant at 8q24. Nat Genet. 2007; 39:631–7. [PubMed: 17401366]
2. Haiman CA, et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat
Genet. 2007; 39:638–44. [PubMed: 17401364]
3. Gudmundsson J, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in
TCF2 protects against type 2 diabetes. Nat Genet. 2007; 39:977–83. [PubMed: 17603485]
4. Eeles RA, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat
Genet. 2008; 40:316–21. [PubMed: 18264097]
5. Thomas G, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat
Genet. 2008; 40:310–5. [PubMed: 18264096]
6. Gudmundsson J, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to
prostate cancer. Nat Genet. 2008; 40:281–3. [PubMed: 18264098]
7. Yeager M, et al. Genome-wide association study of prostate cancer identifies a second risk locus at
8q24. Nat Genet. 2007; 39:645–9. [PubMed: 17401363]
8. Easton DF, et al. Genome-wide association study identifies novel breast cancer susceptibility loci.
Nature. 2007; 447:1087–93. [PubMed: 17529967]
9. Amundadottir LT, et al. A common variant associated with prostate cancer in European and African
populations. Nat Genet. 2006; 38:652–8. [PubMed: 16682969]
10. Tomlinson I, et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant
for colorectal cancer at 8q24.21. Nat Genet. 2007; 39:984–8. [PubMed: 17618284]
11. Zanke BW, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus
on chromosome 8q24. Nat Genet. 2007; 39:989–94. [PubMed: 17618283]
12. Haiman CA, et al. A common genetic risk factor for colorectal and prostate cancer. Nat Genet.
2007; 39:954–6. [PubMed: 17618282]
13. Kiemeney LA, et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat
Genet. 2008; 40:1307–12. [PubMed: 18794855]
14. Ghoussaini M, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J
Natl Cancer Inst. 2008; 100:962–6. [PubMed: 18577746]
15. Duggan D, et al. Two genome-wide association studies of aggressive prostate cancer implicate
putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst. 2007; 99:1836–44.
[PubMed: 18073375]
16. Kote-Jarai Z, et al. Multiple novel prostate cancer predisposition loci confirmed by an international
study: the PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev. 2008; 17:2052–61.
[PubMed: 18708398]
Gudmundsson et al. Page 8
Nat Genet. Author manuscript; available in PMC 2013 February 03.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
17. Rafnar T, et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.
Nat Genet. 2009; 41:221–7. [PubMed: 19151717]
18. Sun J, et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene
at 17q12. Nat Genet. 2008; 40:1153–5. [PubMed: 18758462]
19. Sun J, et al. Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res. 2009;
69:10–5. [PubMed: 19117981]
20. Kutyavin IV, et al. A novel endonuclease IV post-PCR genotyping system. Nucleic Acids
Research. 2006; 34:e128. [PubMed: 17012270]
21. Bentley DR, et al. Accurate whole human genome sequencing using reversible terminator
chemistry. Nature. 2008; 456:53–9. [PubMed: 18987734]
22. Gretarsdottir S, et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat
Genet. 2003; 35:131–8. [PubMed: 14517540]
23. Falk CT, Rubinstein P. Haplotype relative risks: an easy reliable way to construct a proper control
sample for risk calculations. Ann Hum Genet. 1987; 51(Pt 3):227–33. [PubMed: 3500674]
24. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of
disease. J Natl Cancer Inst. 1959; 22:719–48. [PubMed: 13655060]
25. Styrkarsdottir U, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med.
2008; 358:2355–65. [PubMed: 18445777]
26. Pe’er I, et al. Evaluating and improving power in whole-genome association studies using fixed
marker sets. Nat Genet. 2006; 38:663–7. [PubMed: 16715096]
27. Nicolae DL. Testing untyped alleles (TUNA)-applications to genome-wide association studies.
Genet Epidemiol. 2006; 30:718–27. [PubMed: 16986160]
28. Zaitlen N, Kang HM, Eskin E, Halperin E. Leveraging the HapMap correlation structure in
association studies. Am J Hum Genet. 2007; 80:683–91. [PubMed: 17357074]
29. Zheng SL, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J
Med. 2008; 358:910–9. [PubMed: 18199855]
30. Stefansson H, et al. A common inversion under selection in Europeans. Nat Genet. 2005; 37:129–
37. [PubMed: 15654335]
Gudmundsson et al. Page 9
Nat Genet. Author manuscript; available in PMC 2013 February 03.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Gudmundsson et al. Page 10
Ta
bl
e 
1
Su
m
m
ar
y 
as
so
ci
at
io
n 
re
su
lts
 fo
r t
he
 S
N
Ps
 o
n 
3q
21
.3
, 8
q2
4,
 1
9q
13
.2
 a
nd
 1
1q
13
C
as
es
(N
)
C
on
tr
ol
s
(N
)
Fr
eq
ue
nc
y
St
ud
y 
po
pu
la
tio
n
C
as
es
C
on
tr
ol
s
O
R
 (9
5%
 C
I)
P-
va
lu
e
A
. R
es
ul
ts
 fo
r 
rs
10
93
48
53
 [A
] o
r r
s4
85
78
41
 [A
] o
n 3
q2
1.3
Ic
el
an
da
1,
96
8
35
,2
27
0.
29
5
0.
26
9
1.
14
 (1
.06
, 1
.22
)
3.
2E
-0
4
Ch
ic
ag
o,
 Il
lin
oi
s
1,
07
7
1,
00
3
0.
31
3
0.
27
3
1.
21
 (1
.06
, 1
.39
)
4.
4E
-0
3
Fi
nl
an
d
2,
63
8
1,
71
6
0.
33
0
0.
31
9
1.
05
 (0
.96
, 1
.15
)
0.
27
Th
e 
N
et
he
rla
nd
s
1,
08
4
1,
82
7
0.
30
6
0.
28
6
1.
10
 (0
.98
, 1
.24
)
0.
10
N
as
hv
ill
e,
 T
en
ne
ss
ee
59
6
68
7
0.
28
3
0.
27
0
1.
07
 (0
.90
, 1
.27
)
0.
47
Sp
ai
n
81
1
1,
60
5
0.
30
6
0.
31
4
0.
96
 (0
.84
, 1
.09
)
0.
54
A
CS
b
1,
75
8
1,
77
5
0.
30
0
0.
25
8
1.
25
 (1
.12
, 1
.39
)
4.
3E
-0
5
A
TB
Cb
92
8
92
1
0.
30
9
0.
31
9
0.
96
 (0
.84
, 1
.10
)
0.
59
FP
CC
b
65
4
65
7
0.
29
1
0.
27
2
1.
09
 (0
.92
, 1
.29
)
0.
34
H
PF
Sb
59
5
60
9
0.
31
3
0.
27
8
1.
18
 (0
.99
, 1
.40
)
0.
07
0
PL
CO
b
1,
16
7
1,
09
3
0.
30
8
0.
26
6
1.
23
 (1
.08
, 1
.41
)
2.
5E
-0
3
CA
PS
c
49
8
49
4
0.
32
9
0.
28
8
1.
21
 (1
.00
, 1
.46
)
0.
04
5
A
ll 
co
m
bi
ne
dd
13
,7
74
47
,6
14
-
0.
28
4
1.
12
 (1
.08
, 1
.16
)
2.
9E
-1
0
P 
he
t
0.
03
9
I2
46
.4
B.
 R
es
ul
ts
 fo
r 
rs
16
90
20
94
 [G
] o
r r
s1
69
02
10
4 [
T]
 on
 8q
24
Ic
el
an
da
1,
85
8
6,
85
3
0.
16
8
0.
13
6
1.
28
 (1
.15
, 1
.41
)
3.
5E
-0
6
Ch
ic
ag
o,
 Il
lin
oi
s
79
7
75
8
0.
16
6
0.
14
7
1.
16
 (0
.95
, 1
.41
)
0.
14
Fi
nl
an
d
2,
19
7
1,
72
5
0.
24
8
0.
22
2
1.
15
 (1
.03
, 1
.28
)
9.
9E
-0
3
Th
e 
N
et
he
rla
nd
s
83
1
83
7
0.
16
1
0.
13
8
1.
20
 (0
.99
, 1
.44
)
0.
06
6
N
as
hv
ill
e,
 T
en
ne
ss
ee
66
9
73
3
0.
17
0
0.
13
0
1.
37
 (1
.11
, 1
.69
)
3.
0E
-0
3
Sp
ai
n
64
3
95
2
0.
16
2
0.
13
7
1.
21
 (1
.00
, 1
.48
)
0.
05
5
A
CS
b
1,
75
9
1,
77
4
0.
15
6
0.
13
2
1.
22
 (1
.06
, 1
.39
)
4.
3E
-0
3
Nat Genet. Author manuscript; available in PMC 2013 February 03.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Gudmundsson et al. Page 11
C
as
es
(N
)
C
on
tr
ol
s
(N
)
Fr
eq
ue
nc
y
St
ud
y 
po
pu
la
tio
n
C
as
es
C
on
tr
ol
s
O
R
 (9
5%
 C
I)
P-
va
lu
e
A
TB
Cb
92
9
92
0
0.
25
5
0.
19
3
1.
43
 (1
.22
, 1
.67
)
1.
0E
-0
5
FP
CC
b
65
6
65
7
0.
15
2
0.
14
5
1.
06
 (0
.85
, 1
.31
)
0.
61
H
PF
Sb
59
6
61
1
0.
12
7
0.
13
3
0.
93
 (0
.74
, 1
.18
)
0.
57
PL
CO
b
1,
16
7
1,
09
3
0.
14
5
0.
13
7
1.
09
 (0
.92
, 1
.30
)
0.
31
A
ll 
co
m
bi
ne
dd
12
,1
02
16
,9
13
-
0.
15
0
1.
21
 (1
.15
, 1
.26
)
6.
2E
-1
5
P 
he
t
0.
14
I 2
32
.9
C
. R
es
ul
ts
 fo
r r
s4
45
11
4 
[T
] o
n 8
q2
4
Ic
el
an
da
1,
72
7
35
,3
82
0.
71
0
0.
67
2
1.
20
 (1
.11
, 1
.29
)
5.
0E
-0
6
Th
e 
N
et
he
rla
nd
s
91
0
1,
83
2
0.
67
6
0.
65
0
1.
13
 (1
.00
, 1
.27
)
0.
04
8
Sp
ai
n
49
0
1,
38
7
0.
66
0
0.
62
4
1.
17
 (1
.01
, 1
.36
)
0.
04
1
A
CS
1,
75
7
1,
76
8
0.
65
1
0.
61
8
1.
15
 (1
.05
, 1
.27
)
4.
0E
-0
3
A
TB
C
92
5
91
9
0.
70
2
0.
66
1
1.
22
 (1
.06
, 1
.40
)
6.
6E
-0
3
FP
CC
65
5
65
5
0.
64
7
0.
63
5
1.
05
 (0
.90
, 1
.24
)
0.
52
H
PF
S
59
5
60
8
0.
61
3
0.
63
3
0.
91
 (0
.77
, 1
.07
)
0.
26
PL
CO
1,
17
5
1,
10
0
0.
64
1
0.
61
8
1.
13
 (1
.00
, 1
.28
)
5.
7E
-0
2
A
ll 
co
m
bi
ne
dd
8,
23
4
43
,6
51
-
0.
63
9
1.
14
 (1
.10
, 1
.19
)
4.
7E
-1
0
P 
he
t
0.
13
I 2
37
.0
D
. R
es
ul
ts
 fo
r 
rs
81
02
47
6 
[C
] o
n 1
9q
13
.2
Ic
el
an
da
1,
94
1
35
,3
30
0.
51
7
0.
49
5
1.
09
 (1
.03
, 1
.17
)
6.
4E
-0
3
Ch
ic
ag
o,
 Il
lin
oi
s
1,
08
6
1,
17
2
0.
61
2
0.
57
9
1.
15
 (1
.02
, 1
.29
)
0.
02
4
Fi
nl
an
d
2,
62
9
1,
73
9
0.
48
1
0.
43
5
1.
21
 (1
.11
, 1
.31
)
2.
1E
-0
5
Th
e 
N
et
he
rla
nd
s
1,
08
6
1,
83
0
0.
56
7
0.
52
8
1.
17
 (1
.05
, 1
.30
)
4.
2E
-0
3
N
as
hv
ill
e,
 T
en
ne
ss
ee
59
6
68
9
0.
56
5
0.
55
3
1.
05
 (0
.90
, 1
.23
)
0.
55
Sp
ai
n
72
8
1,
38
9
0.
64
1
0.
61
9
1.
10
 (0
.96
, 1
.25
)
0.
16
Nat Genet. Author manuscript; available in PMC 2013 February 03.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Gudmundsson et al. Page 12
C
as
es
(N
)
C
on
tr
ol
s
(N
)
Fr
eq
ue
nc
y
St
ud
y 
po
pu
la
tio
n
C
as
es
C
on
tr
ol
s
O
R
 (9
5%
 C
I)
P-
va
lu
e
A
CS
1,
75
5
1,
76
6
0.
57
4
0.
55
1
1.
10
 (1
.00
, 1
.21
)
0.
04
3
A
TB
C
92
6
91
9
0.
47
3
0.
46
1
1.
05
 (0
.93
, 1
.20
)
0.
43
FP
CC
65
6
65
5
0.
60
7
0.
56
3
1.
19
 (1
.02
, 1
.40
)
0.
02
7
H
PF
S
59
5
60
9
0.
57
4
0.
57
1.
03
 (0
.88
, 1
.21
)
0.
74
PL
CO
1,
17
5
1,
10
0
0.
57
1
0.
54
5
1.
10
 (0
.98
, 1
.24
)
0.
11
A
ll 
co
m
bi
ne
dd
13
,1
73
47
,1
98
-
0.
53
6
1.
12
 (1
.08
, 1
.15
)
1.
6E
-1
1
P 
he
t
0.
63
I 2
0.
0
E.
 R
es
ul
ts
 fo
r 
rs
11
22
85
65
 [A
] o
n 1
1q
13
.
Ic
el
an
da
18
09
78
3
0.
21
0
0.
17
7
1.
24
 (1
.06
,1.
43
)
5.
7E
-0
3
Ch
ic
ag
o,
 Il
lin
oi
s
75
5
87
8
0.
23
5
0.
21
0
1.
16
 (0
.98
,1.
37
)
8.
0E
-0
2
Fi
nl
an
d
26
43
16
89
0.
21
0
0.
16
9
1.
30
 (1
.16
,1.
45
)
3.
2E
-0
6
Th
e 
N
et
he
rla
nd
s
99
2
17
81
0.
22
9
0.
20
2
1.
17
 (1
.02
,1.
34
)
0.
02
1
N
as
hv
ill
e,
 T
en
ne
ss
ee
59
2
68
5
0.
29
1
0.
22
3
1.
43
 (1
.20
,1.
71
)
8.
5E
-0
5
Sp
ai
n
39
4
13
99
0.
24
0
0.
22
4
1.
09
 (0
.91
,1.
30
)
0.
34
A
ll 
co
m
bi
ne
dd
71
85
72
15
-
0.
20
1
1.
23
 (1
.16
, 1
.31
)
6.
7E
-1
2
P 
he
t
0.
26
I 2
23
.3
A
ll 
P 
va
lu
es
 sh
ow
n 
ar
e 
tw
o-
sid
ed
. S
ho
w
n 
ar
e 
th
e 
co
rre
sp
on
di
ng
 n
um
be
rs
 o
f c
as
es
 a
nd
 c
on
tro
ls 
(N
), a
lle
lic
 fr
eq
ue
nc
ies
 of
 va
ria
nts
 in
 af
fec
ted
 an
d c
on
tro
l in
div
idu
als
, th
e a
lle
lic
 od
ds
-ra
tio
 (O
R)
 w
ith
 95
%
co
n
fid
en
ce
 in
te
rv
al
 (9
5%
 C
I) 
an
d P
 
v
al
ue
. A
lso
 sh
ow
n,
 a
re
 th
e 
P-
va
lu
es
 fo
r t
he
 h
et
er
og
en
ei
ty
 o
f t
he
 O
Rs
 (P
he
t) 
for
 al
l s
tud
y g
rou
ps
 as
 w
ell
 as
 I2
 
w
hi
ch
 li
es
 b
et
w
ee
n 
0%
 a
nd
 1
00
%
 a
nd
 d
es
cr
ib
es
 th
e
pr
op
or
tio
n 
of
 to
ta
l v
ar
ia
tio
n 
in
 st
ud
y 
es
tim
at
es
 th
at
 is
 d
ue
 to
 h
et
er
og
en
ei
ty
.
a R
es
ul
ts 
pr
es
en
te
d 
fo
r I
ce
la
nd
 w
er
e 
ad
jus
ted
 fo
r r
ela
ted
ne
ss 
(se
e O
nli
ne
 M
eth
od
s).
b T
he
 re
su
lts
 fo
r t
he
 fi
ve
 C
G
EM
S 
gr
ou
ps
 o
n 
3q
21
.3
 a
nd
 8
q2
4 
ar
e 
fo
r t
he
 S
N
Ps
 rs
48
57
84
1 
[A
] a
nd
 rs
16
90
21
04
[T
], 
wh
ich
 ar
e h
igh
ly 
co
rre
lat
ed
 w
ith
 rs
10
93
48
53
[A
] a
nd
 rs
16
90
20
94
8G
], 
res
pe
cti
ve
ly 
(D
’ a
nd
r2
 
>
 0
.9
6 
ac
co
rd
in
g 
to
 Ic
el
an
di
c a
nd
 C
EU
 H
ap
M
ap
 d
at
a).
c R
es
ul
ts 
fo
r t
he
 S
w
ed
ish
 C
A
PS
 st
ud
y 
gr
ou
p 
ar
e 
fo
r r
s1
09
34
85
3[
A]
 pu
bli
sh
ed
 by
 D
ug
ga
n e
t a
l.1
5
d F
or
 th
e 
co
m
bi
ne
d 
stu
dy
 p
op
ul
at
io
ns
, t
he
 re
po
rte
d 
co
nt
ro
l f
re
qu
en
cy
 w
as
 th
e 
av
er
ag
e,
 u
nw
ei
gh
te
d 
co
nt
ro
l f
re
qu
en
cy
 o
f t
he
 in
di
vi
du
al
 p
op
ul
at
io
ns
, w
hi
le
 th
e 
O
R 
an
d 
th
e 
P 
v
al
ue
 w
er
e 
es
tim
at
ed
 u
sin
g 
th
e
M
an
te
l-H
ae
ns
ze
l m
od
el
.
Nat Genet. Author manuscript; available in PMC 2013 February 03.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Gudmundsson et al. Page 13
Ta
bl
e 
2
A
ss
oc
ia
tio
n 
re
su
lts
 fr
om
 a
 G
W
A
S 
in
 Ic
el
an
d 
fo
r v
ar
ia
nt
s r
ep
or
te
d 
to
 co
nf
er
 ri
sk
 o
f p
ro
st
at
e c
an
ce
r i
de
nt
ifi
ed
 th
ro
ug
h 
G
W
A
S
M
ar
ke
r,
 [r
isk
 al
lel
e] 
an
d (
co
rr
ela
ted
m
a
rk
er
(s)
)a
Lo
cu
s
C
as
es
(N
)
C
on
tr
ol
s
(N
)
Fr
eq
ue
nc
y
O
R
 (9
5%
 C
I)
P-
va
lu
e
C
as
es
C
on
tr
ol
s
rs
27
10
64
6 
[A
], 
(rs
72
10
48
)6
2p
15
1,
88
2
35
,1
45
0.
22
4
0.
20
3
1.
14
 (1
.05
, 1
.24
)
2.
5×
10
−
3
rs
26
60
75
3 
[T
]4
3p
12
1,
72
5
35
,3
62
0.
11
0
0.
10
0
1.
11
 (0
.99
, 1
.25
)
0.
07
5
rs
40
16
81
 [C
]17
5p
15
1,
96
2
35
,4
00
0.
56
2
0.
54
7
1.
07
 (1
.00
, 1
.14
)
0.
06
6
rs
93
64
55
4 
[T
]4
6q
25
1,
72
5
35
,3
99
0.
32
2
0.
30
9
1.
06
 (0
.99
, 1
.15
)
0.
11
rs
10
48
65
67
 [G
]5
7p
15
1,
72
5
35
,3
92
0.
78
7
0.
76
5
1.
13
 (1
.04
, 1
.24
)
4.
4×
10
−
3
rs
64
65
65
7 
[C
]4
7q
21
1,
72
4
35
,3
58
0.
43
2
0.
42
1
1.
04
 (0
.97
, 1
.12
)
0.
26
rs
14
47
29
5 
[A
]9
8q
24
 (1
)
1,
82
1
35
,4
70
0.
16
5
0.
11
1
1.
58
 (1
.43
, 1
.74
)
2.
2×
10
−
19
rs
16
90
19
79
 [A
]1
8q
24
 (2
)
1,
72
6
35
,4
03
0.
07
3
0.
04
2
1.
80
 (1
.55
, 2
.09
)
2.
5×
10
−
14
rs
69
83
26
7 
[G
]7
8q
24
 (3
)
1,
72
4
35
,3
67
0.
58
1
0.
55
1
1.
13
 (1
.05
, 1
.22
)
7.
5×
10
−
4
rs
15
71
80
1 
[A
]15
9q
33
 b
1,
72
1
35
,3
03
0.
26
1
0.
27
6
0.
93
 (0
.85
, 1
.01
)
0.
06
8
rs
10
99
39
94
 [T
]4,
5
10
q1
1
1,
72
7
35
,3
97
0.
41
0
0.
38
4
1.
11
 (1
.04
, 1
.20
)
3.
7×
10
−
3
rs
49
62
41
6 
[C
]5
10
q2
6c
1,
72
4
35
,3
22
0.
22
3
0.
22
1
1.
02
 (0
.94
, 1
.11
)
0.
68
rs
10
89
64
50
 [G
], 
(rs
10
89
64
49
5 ,
 
rs
79
3 
13
42
4 )
11
q1
3
1,
95
1
35
,3
94
0.
50
1
0.
46
9
1.
13
 (1
.06
, 1
.21
)
2.
5×
10
−
4
rs
44
30
79
6 
[A
]3
17
q1
2
1,
72
6
35
,3
97
0.
55
9
0.
51
7
1.
19
 (1
.10
, 1
.28
)
8.
3×
10
−
6
rs
11
64
97
43
 [G
]18
17
q1
2
1,
74
7
35
,4
05
0.
81
2
0.
79
9
1.
09
 (0
.99
, 1
.19
)
0.
06
6
rs
18
59
96
2 
[G
]3
17
q2
4.
3
1,
74
6
35
,1
24
0.
49
3
0.
45
5
1.
16
 (1
.08
, 1
.25
)
3.
7×
10
−
5
rs
27
35
83
9 
[G
]4
19
q1
3.
33
1,
72
6
35
,3
76
0.
87
9
0.
86
5
1.
14
 (1
.02
, 1
.27
)
0.
02
1
rs
96
23
11
7 
[C
]19
22
q1
3 
b
1,
72
4
35
,3
89
0.
20
8
0.
20
8
1.
00
 (0
.91
, 1
.10
)
0.
99
rs
59
45
57
2 
[A
]6 ,
 
(rs
59
45
 61
94
)
X
p1
1
1,
89
9
35
,3
84
0.
41
6
0.
36
9
1.
22
 (1
.11
, 1
.34
)
6.
1×
10
−
5
a S
ho
w
n 
in
 th
e 
ta
bl
e 
ar
e 
G
W
A
S 
fro
m
 Ic
el
an
d 
fo
r v
ar
ia
nt
s t
ha
t h
av
e 
be
en
 id
en
tif
ie
d 
th
ro
ug
h 
G
W
A
S 
re
su
lts
 (p
ub
lis
he
d u
p t
o F
eb
rua
ry 
20
09
) a
nd
 th
e o
rig
ina
l p
ub
lic
ati
on
(s)
. H
igh
ly 
co
rre
lat
ed
 m
ark
ers
 ar
e
sh
ow
n 
in
 p
ar
en
th
es
is 
as
 w
el
l a
s t
he
 st
ud
y 
re
po
rti
ng
 th
em
. A
ll 
P 
va
lu
es
 a
re
 tw
o-
sid
ed
. S
ho
w
n 
ar
e 
th
e 
co
rre
sp
on
di
ng
 n
um
be
rs
 o
f c
as
es
 a
nd
 c
on
tro
ls 
(N
), a
lle
lic
 fr
eq
ue
nc
ies
 of
 va
ria
nts
 in
 af
fec
ted
 an
d c
on
tro
l
in
di
vi
du
al
s, 
th
e 
al
le
lic
 o
dd
s-
ra
tio
 (O
R)
 w
ith
 95
% 
co
nfi
de
nc
e i
nte
rva
l (
95
% 
CI
) a
nd
 P 
v
al
ue
 a
dju
ste
d f
or 
rel
ate
dn
ess
.
b T
he
 o
rig
in
al
 re
su
lts
 p
ub
lis
he
d 
fo
r t
he
 lo
ci
 o
n 
9q
33
15
 
an
d 
22
q1
31
9  
w
er
e 
fro
m
 a
 st
ud
y 
on
 c
as
es
 w
ith
 a
gg
re
ss
iv
e 
pr
os
ta
te
 c
an
ce
r. 
Re
su
lts
 fo
r t
he
se
 tw
o 
lo
ci
 in
 Ic
el
an
di
c 
ca
se
s (
N 
= 6
93
) w
ith
 m
ore
 ag
gre
ssi
ve
pr
os
ta
te
 c
an
ce
r (
Gl
ea
so
n s
co
re 
>6
 an
d/o
r T
3 o
r h
igh
er 
an
d/o
r n
od
e p
os
itiv
e a
nd
/or
 m
eta
sta
tic
 di
sea
se)
, u
sin
g t
he
 sa
me
 se
t o
f c
on
tro
ls,
 w
ere
 no
t s
ign
ifi
ca
nt 
(rs
15
71
80
1; 
OR
ag
gr
 
=
 0
.9
0 
an
d 
P 
= 
0.
08
0,
rs
96
23
11
7;
 O
R a
gg
r =
 1
.0
0 
an
d 
P 
= 
0.
94
).
Nat Genet. Author manuscript; available in PMC 2013 February 03.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Gudmundsson et al. Page 14
c T
he
 S
N
P 
m
ar
ke
r, 
rs
49
62
41
6,
 at
 th
e 1
0q
26
 lo
cu
s i
s n
ot
 o
n 
th
e I
llu
m
in
a H
ap
30
0 
ch
ip
, r
es
ul
ts 
sh
ow
n 
fo
r i
t a
re
 b
as
ed
 o
n 
a w
ei
gh
te
d 
co
m
bi
na
tio
n 
of
 tw
o 
m
ar
ke
r h
ap
lo
ty
pe
 g
en
er
at
ed
 fr
om
 rs
70
77
27
5 
an
d
rs
89
38
56
 th
at
 ar
e p
re
se
nt
 o
n 
th
e c
hi
p 
an
d 
ta
g 
th
e S
N
P 
(rs
49
62
41
6).
Nat Genet. Author manuscript; available in PMC 2013 February 03.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Gudmundsson et al. Page 15
Table 3
Population distribution in Iceland of ORs for 22 prostate cancer susceptibility variants
OR-range Population percentage
< 0.5 9.5%
0.5–0.75 25.2%
0.75–1 24.7%
1–1.5 27.6%
1.5–2 9.1%
2–2.5 2.7%
> 2.5 1.3%
Results from a multi-variant risk model analysis for prostate cancer in Iceland based on susceptibility variants in tables 1 and 2. Results from
Iceland were used for all variants in table 1 and 2, except rs1571801 on 9q33 since its effect was in the opposite direction, and rs10896450 on
11q13 for which data for the refinement SNP in table 1 was used. Odds ratios (OR) were calculated for all possible genotype combinations based
on 22 variants and expressed relative to the average general population risk, assuming the multiplicative model between variants. The combined
OR estimates were then divided into OR-ranges and presented along with the percentage of the population within each OR-range. The general
population risk was determined using a frequency-weighted average risk for all possible genotypes.
Nat Genet. Author manuscript; available in PMC 2013 February 03.
